Vivus weight-loss treatment Qsymia wins FDA nod

The FDA cleared Vivus' weight-loss treatment Qsymia, a combination of anti-seizure drug topiramate and generic weight-loss treatment phentermine, for obese adults or overweight adults with high cholesterol, diabetes or hypertension. The drug is the second weight-loss treatment approved by the FDA after 13 years without approvals.

View Full Article in:

New York Times (tiered subscription model), The · American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations